Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 3. Today at the San Antonio Breast Cancer Symposium, real world economics shared…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 3. Participants in the San Antonio Breast Cancer Symposium today heard evidence that…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 4. In one of our final reports from the San Antonio Breast Cancer…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. Several papers describing research into the screening and management of breast cancer…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. Several papers describing research into the screening and management of breast cancer…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 1. The long-awaited AZURE Trial – The Carry-Over Effect of Adjuvant Zoledronic Acid:…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 1. Several papers describing research into the screening and management of breast cancer…
NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer…
This week, the 2010 CTRC-AACR San Antonio Breast Cancer Symposium kicks off. The Doctor’s Channel provides leading news coverage of all the late breaking trial and study data…
NEW YORK (Reuters Health) – The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who…
